Cellular Bio on go for CAR-T blood cancer study in China

• Enrollment is underway in a China-based Phase 1 study, CARD-1, assessing Cellular Biomedicine Group's (NASDAQ:CBMG) C-CAR011 for the treatment of patients with treatment-resistant diffuse large B-cell lymphoma (DLBCL). Top-line data are expected in H2 2017. A Phase 2 study will be initiated as soon as feasible.
• C-CAR011 is a CAR-T therapy engineered and manufactured at the company's GMP site in China. The company acquired the technology from Beijing's PLA General Hospital. The study will be conducted at the Jiangsu Provincial People's Hospital in Nanjing.